Specific use of nitrated allopurinol to treat heart failure and angina
Heart disease is the leading cause of death in the US and is, consequently, associated with a high economic burden, due to the ~$320 billion cost in health care and loss of productivity. Oxidative stress induced by reactive oxygen species (ROS) has been tightly linked with cardiovascular conditions, yet no therapies have been approved to target this aspect of heart disease. Therefore, effective therapeutics that target this aspect of cardiovascular disease could have great clinical benefit.
Dr. Jonathan Stamler, a cardiologist who now serves as the Reitman Family Distinguished Chair of Cardiovascular Innovation at University Hospitals Case Medical Center, has discovered that a nitrated form of the ROS-producing enzyme inhibitor, allopurinol, promotes significant enhancements in myocardial contraction compared to the non-derivatized form. Furthermore, nitrated allopurinol was demonstrated to be safe when given to patients with cardiovascular-associated conditions, and moderate improvements in symptoms were observed. Thus, this therapeutic may have potential applications for various cardiovascular-associated conditions, including angina, heart failure, and myocardial infarction.
There are currently no approved therapies that target the oxidative stress associated with cardiovascular disease. While allopurinol has failed to demonstrate global benefits against cardiovascular diseases in clinical testing, Dr. Stamler’s findings suggest significant clinical advantages of nitrated allopurinol.